Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC

Over the last decade, the revolution in genomic medicine and immunotherapy has led to a rapid expansion of the therapeutic landscape in advanced non-small cell lung cancer (NSCLC). This progress is now slowly starting to reach those with earlier stage NSCLC, including localised stage I –II disease and locally advanced stage III disease. Unlike other early-stage diseases, including breast and colon cancer, the prognosis in NSCLC is poorer and many patients experience relapse. Despite curative-intent therapy, over 20% of patients with stage I NSCLC, 50% with stage II, and a stagge ring 60% with stage IIIA are dead within 5 years of curative-intent therapy [1].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research